chiara cremolini
chiara cremolini
Assistant Professor, University of Pisa
Verified email at unipi.it
TitleCited byYear
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
5832014
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715, 2009
5432009
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795, 2015
5392015
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
4602009
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
4272015
Primary tumor location as a prognostic factor in metastatic colorectal cancer
F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ...
JNCI: Journal of the National Cancer Institute 107 (3), 2015
2482015
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ...
The lancet oncology 11 (9), 845-852, 2010
2382010
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European Journal of Cancer 50 (1), 57-63, 2014
1422014
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ...
Journal of the National Cancer Institute 103 (1), 21-30, 2010
1352010
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage …
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458, 2010
1212010
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1042015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
1022015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ...
Annals of Oncology 26 (4), 724-730, 2015
1022015
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ...
British journal of cancer 104 (8), 1262, 2011
962011
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a …
L Fornaro, S Lonardi, G Masi, F Loupakis, F Bergamo, L Salvatore, ...
Annals of oncology 24 (8), 2062-2067, 2013
882013
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921, 2015
762015
First-line chemotherapy for mCRC—a review and evidence-based algorithm
C Cremolini, M Schirripa, C Antoniotti, R Moretto, L Salvatore, G Masi, ...
Nature reviews Clinical oncology 12 (10), 607, 2015
752015
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
F Pietrantonio, C Vernieri, G Siravegna, A Mennitto, R Berenato, ...
Clinical cancer research 23 (10), 2414-2422, 2017
732017
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
M Schirripa, C Cremolini, F Loupakis, M Morvillo, F Bergamo, F Zoratto, ...
International journal of cancer 136 (1), 83-90, 2015
672015
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi, P Frumento, ...
BMC cancer 11 (1), 247, 2011
662011
The system can't perform the operation now. Try again later.
Articles 1–20